Media reports suggests that Aurobindo Pharma has received USFDA approval for gTreximet. The orange book search indicates that approval was given on February 15, 2018. Treximet tablet (Naproxen Sodium; Sumatriptan Succinate) is made by Pernix.The drug originally belongs to GSK Pharma, who has sold the US rights of this drug to Pernix. Pernix has agreed to pay GSK $250 million upfront for the US rights as well as $17 million additional payments on approval of the drug in US for paediatric use. Treximet is used to treat acute migraine headaches with or without aura in patients, 12 years of age and older.
Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.CapitalStars Investment Adviser: SEBI Registration Number: INA000001647
No comments:
Post a Comment